Astellas Pharma Inc.

Business Description

Astellas rests on a small number of large products. XTANDI (enzalutamide) for prostate cancer accounts for about 45% of revenue; Padcev (enfortumab vedotin) for bladder cancer, developed with Pfizer and Seagen, and Prograf (tacrolimus), the transplant immunosuppressant still used as a standard of care three decades after launch, contribute roughly a tenth each, and the overactive-bladder franchise sold as Betanis, Myrbetriq and Betmiga close to another 9%. The therapeutic focus runs across oncology, urology, transplantation immunology and ophthalmology.

That concentration is the investment case: the loss of exclusivity on XTANDI is the largest single event ahead of the company, and strategy amounts to a race to replace it before it arrives. Padcev, IZERVAY for geographic atrophy — acquired with Iveric Bio — and VEOZAH (Veoza outside the United States) for menopausal hot flushes are the designated successors, while research pushes into cell and gene therapy and other advanced modalities. With around 87% of revenue earned abroad, results also swing with the yen. Astellas took its present form in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical; the legal entity dates back to 1939. It reports on a March fiscal year.

Corporate Data

Latest Coverage

• August 5, 2026 Astellas Q1 Profit More Than Doubles to ¥141.8 Billion as Focus Products and Weak Yen Lift Revenue 27%
• April 27, 2026 Astellas FY26 Net Profit Nearly Quintuples to ¥292 Billion as Operating Profit Recovers 832% from Impairment-Plagued Base; Annual Dividend Lifted to ¥78